Literature DB >> 1810737

Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.

P R Murray1, S D Allen, M E Erwin, E H Gerlach, R N Jones, F P Koontz, M A Pfaller, J A Washington.   

Abstract

The activity of RU29246, the active metabolite of the oral cephalosporin ester HR916, was compared in a multicenter study with that of the four oral beta-lactam antibiotics cephalexin, cefaclor, cefixime and amoxicillin/clavulanate (amoxicillin/CA). RU29246 was generally 2- to 8-fold more active than the other oral cephalosporins and comparable to amoxicillin/CA against staphylococci, and was the most active cephalosporin against group B streptococci. All four cephalosporins were ineffective against enterococci. RU29246 was the only cephalosporin consistently active against Acinetobacter, but all beta-lactam antibiotics had poor activity against Pseudomonas spp. and Xanthomonas maltophilia. RU29246 was comparable to cefixime and more active than the other cephalosporins against members of the family Enterobacteriaceae. However, all of the antibiotics had poor activity against Enterobacter cloacae and Serratia marcescens. Quality control reference ranges for the quality control organisms Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 are proposed for the broth dilution method based on data derived from this multicenter study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810737     DOI: 10.1007/BF01972510

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

2.  Preliminary in-vitro studies of BMY-28232, the active metabolite of the BMY-28271 cephalosporin ester.

Authors:  R M Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

3.  In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.

Authors:  A Tamura; R Okamoto; T Yoshida; H Yamamoto; S Kondo; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  FK 482, a new orally active cephalosporin synthesis and biological properties.

Authors:  Y Inamoto; T Chiba; T Kamimura; T Takaya
Journal:  J Antibiot (Tokyo)       Date:  1988-06       Impact factor: 2.649

5.  Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.

Authors:  H C Neu; G Saha; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  In vitro antibacterial activity of FK482, a new orally active cephalosporin.

Authors:  Y Mine; T Kamimura; Y Watanabe; S Tawara; Y Matsumoto; F Shibayama; H Kikuchi; T Takaya; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1988-12       Impact factor: 2.649

7.  In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester.

Authors:  R N Jones; M E Erwin; M S Barrett; B M Briggs; D M Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Nov-Dec       Impact factor: 2.803

8.  Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella.

Authors:  R N Jones; M E Erwin; M S Barrett
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Nov-Dec       Impact factor: 2.803

  8 in total
  1 in total

1.  Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.

Authors:  K W Yu; N X Chin; H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.